Avid Bioservices Inc (CDMO)

[jazzbeerman]

underwriter, Avastin plus carboplatin/paclitaxel:


(The Peregrine bavi combo trial (most likely) used carboplatin/paclitaxel plus bavituximab in lung cancer patients.)



underwriter,

There's a lot of Bevacizumab (Avastin) trial data out there for you to explore, and I think you'll be very pleased when you compare. You should have a look around..



Here's a phase 2 trial, (what's typically termed an "efficacy trial", as opposed to a phase 1 "safety" trial), using avastin in combo w/carboplatin/paclitaxel, compared to carboplatin/paclitaxel alone, in Advanced or Metastatic Non-Small-Cell Lung Cancer.

NOTE: While this patient population was advanced/metastatic/recurrent, they had NOT grown resistant (yet) to carboplatin/palitaxel, as the patient pool in the Indian bavi combo trial had. (BIG difference).





--------------------


RESULTS: Compared with the control arm, treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) resulted in a higher response rate (31.5% v 18.8%), longer median time to progression (7.4 v 4.2 months) and a modest increase in survival (17.7 v 14.9 months). Of the 19 control patients that crossed over to single-agent bevacizumab, five experienced stable disease, and 1-year survival was 47%. Bleeding was the most prominent adverse event and was manifested in two distinct clinical patterns; minor mucocutaneous hemorrhage and major hemoptysis. Major hemoptysis was associated with squamous cell histology, tumor necrosis and cavitation, and disease location close to major blood vessels.

http://jco.ascopubs.org/cgi/content/abstract/22/11/2184

--------------------


NOTE: With that 31.5% "response rate", they're talking "overall response", ("ORR") which is complete, partial, and stable response combined....



j